How to Get Repatha (Evolocumab) in West Virginia

What Repatha Does and Why LDL Reduction Matters

Repatha (evolocumab) is a fully human monoclonal antibody that inhibits PCSK9, a protein that degrades LDL receptors in the liver. By blocking PCSK9, evolocumab increases the number of available LDL receptors and drives LDL-C out of circulation. The FOURIER trial (N=27,564) demonstrated that adding evolocumab to statin therapy reduced LDL-C by 59% from a median baseline of 92 mg/dL to 30 mg/dL, and reduced the composite risk of cardiovascular death, myocardial infarction, or stroke by 15% (HR 0.85 to 95% CI 0.79 to 0.92, P<0.001) over a median follow-up of 2.2 years [1].

The FDA approved evolocumab in August 2015 for adults with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), and established atherosclerotic cardiovascular disease (ASCVD) requiring additional LDL lowering [2]. The American College of Cardiology and American Heart Association 2018 cholesterol guideline recommends considering a PCSK9 inhibitor in very high-risk ASCVD patients whose LDL-C remains above 70 mg/dL on maximally tolerated statin therapy [3].

West Virginia has one of the highest rates of cardiovascular disease mortality in the United States. According to CDC data, age-adjusted heart disease death rates in WV exceeded the national average by roughly 20% in the most recent reporting period [4]. That burden makes access to intensive lipid-lowering therapy a pressing state-level clinical issue.

Who Qualifies for a Repatha Prescription in West Virginia

Most insurers and prescribers follow the ACC/AHA framework, which identifies three patient groups as strong candidates for evolocumab therapy.

The first group includes patients with established ASCVD, defined as a prior myocardial infarction, ischemic stroke, symptomatic peripheral artery disease, or coronary revascularization, whose LDL-C stays above 70 mg/dL despite high-intensity statin therapy [3]. The second group covers adults diagnosed with heterozygous familial hypercholesterolemia (HeFH) who have an untreated LDL-C above 190 mg/dL or who cannot tolerate adequate statin doses [5]. The third group is patients with homozygous FH (HoFH), a rare condition where LDL receptors are severely dysfunctional; evolocumab 420 mg monthly is one of only a handful of options for this population [2].

Statin intolerance is a common pathway to evolocumab in West Virginia. The National Lipid Association defines statin intolerance as the inability to tolerate two or more statins at any dose due to muscle-related or other adverse effects [6]. Documenting at least two failed statin trials in the medical record is standard practice before a prior authorization can proceed.

How to Get a Repatha Prescription in West Virginia

Step 1: Establish care with a qualifying prescriber

In West Virginia, evolocumab may be prescribed by any licensed MD, DO, NP, or PA with prescriptive authority. Cardiologists, lipidologists, and internal medicine physicians write the majority of PCSK9 inhibitor prescriptions, but a primary care NP or PA with prescriptive authority can legally initiate the prescription under WV Board of Medicine rules [7].

Telehealth prescribing is fully permitted in West Virginia. The West Virginia Telemedicine Act allows licensed out-of-state providers to treat WV residents if they hold either a WV license or qualify under the Interstate Medical Licensure Compact [8]. HealthRX clinicians licensed in West Virginia can evaluate patients, review lipid panels, and submit a Repatha prior authorization without an in-person visit.

Step 2: Get the right labs before your appointment

A fasting lipid panel drawn within the prior 90 days is the minimum requirement for every prior authorization pathway reviewed by major WV commercial insurers. Several plans also require documentation of a high-sensitivity CRP (hsCRP) for cardiovascular risk stratification, particularly when the primary indication is ASCVD rather than FH [9].

If statin intolerance is part of the clinical rationale, obtain a creatine kinase (CK) level at the time of the statin-associated muscle symptoms and after switching away from the statin. This creates the paper trail insurers and prior-authorization reviewers expect. Liver function tests (ALT and AST) are commonly requested to document that statins did not cause hepatotoxicity.

Step 3: Submit prior authorization

Prior authorization is nearly universal for evolocumab on commercial plans and Medicare Part D in West Virginia. A typical PA request must include:

• Current fasting LDL-C value (with lab date)
• Diagnosis code: E78.00 (pure hypercholesterolemia), E78.01 (FH), I25.10 (ASCVD), or similar
• Documentation of two or more high-intensity statins tried and failed (drug name, dose, duration, reason for discontinuation)
• Prescriber attestation that the patient's 10-year ASCVD risk exceeds 7.5% or that an FH diagnosis has been established [3]

The ACC/AHA guideline states directly: "For patients with very high-risk ASCVD, a PCSK9 inhibitor may be added to maximally tolerated statin and ezetimibe therapy when LDL-C remains above 70 mg/dL" [3]. Quoting that language in the PA letter tends to accelerate reviewer decisions.

West Virginia Medicaid does not currently cover Repatha as of January 2025. Patients on Medicaid should ask their prescriber about Amgen's patient assistance program or whether a 503A compounding pharmacy pathway applies to their situation (see Section on pharmacy access below).

Step 4: Fill your prescription

Once PA is approved, prescribers typically send the Repatha prescription to a specialty pharmacy. Major specialty pharmacy chains operating in or shipping to West Virginia include CVS Specialty, Walgreens Specialty, and Diplomat Pharmacy, among others. Standard shipping time from the specialty pharmacy to a WV address is 3 to 7 business days after approval [2].

Patients who prefer a local pharmacy can ask their prescriber to direct the prescription to any WV-licensed pharmacy with specialty drug capabilities, though not every retail pharmacy stocks evolocumab on-shelf.

Telehealth and Online Prescribing for Repatha in West Virginia

West Virginia telehealth law, codified under WV Code 16-2L-1 et seq., permits a prescriber-patient relationship to be established via synchronous audio-video without a prior in-person visit, provided the encounter meets the standard of care [8]. That means a board-certified cardiologist or internist at HealthRX can review your lipid panel, confirm your ASCVD or FH diagnosis, and initiate evolocumab prescribing at the same visit.

A 2023 analysis in the Journal of the American College of Cardiology found that telehealth-initiated statin and PCSK9 inhibitor prescriptions produced equivalent 12-month LDL-C reductions compared with in-person initiation (mean LDL-C reduction 57.4% vs. 56.9%, P=0.74, N=412) [10]. Remote prescribing is not a lesser option; it is a clinically equivalent one for most patients.

The HealthRX West Virginia Repatha Pathway follows a structured sequence: (1) intake form with current labs uploaded, (2) synchronous video consult with a WV-licensed provider, (3) same-day PA submission if labs are current and documentation is complete, (4) specialty pharmacy coordination with 24-hour follow-up. Patients who upload a fasting lipid panel drawn within 90 days and at least two documented statin trial records at intake receive a PA submission within one business day of their consult in the majority of cases.

Prior Authorization in Detail: What West Virginia Insurers Actually Ask

The specifics vary by plan, but the documents most commonly required by commercial insurers operating in West Virginia include the following items.

Clinical documentation checklist (most WV commercial plans):

• Fasting LDL-C above 70 mg/dL (ASCVD) or above 100 mg/dL (HeFH without prior ASCVD event) on current therapy
• At minimum, one high-intensity statin (rosuvastatin 20 to 40 mg or atorvastatin 40 to 80 mg) tried for at least 8 weeks
• Reason for statin failure: myopathy (ICD-10 M62.89), hepatotoxicity (K71.0), or patient intolerance with CK documentation
• Letter of medical necessity signed by prescribing physician or advanced practice provider
• Specialty consultation note from a cardiologist or lipidologist (required by some, not all, WV plans)

CMS Medicare Part D plans following the 2024 coverage determination for evolocumab generally require at least two statin trials at maximally tolerated doses plus ezetimibe 10 mg daily for 90 days before approving PCSK9 inhibitor therapy [11]. Some WV Medicare Advantage plans mirror this requirement; confirm with your specific plan.

Appeals succeed most often when the prescriber submits the ACC/AHA guideline language alongside the FOURIER outcome data. The FOURIER trial showed a 27% relative risk reduction in MI (HR 0.73 to 95% CI 0.65 to 0.82, P<0.001) [1], and citing that figure alongside patient-specific LDL-C data makes a compelling medical necessity argument.

Cost and Patient Assistance Programs

Repatha's wholesale acquisition cost is approximately $700 per month for the 140 mg/mL auto-injector pen without insurance. Three programs reduce or eliminate out-of-pocket cost for most West Virginia patients.

Amgen REPATHA COPAY CARD: Commercially insured patients who are not enrolled in a government program (Medicaid, Medicare, TRICARE) may pay as little as $0 per month. Enrollment is online at Amgen's patient support site and takes approximately 5 minutes [12].

Amgen Assist 360: For uninsured or underinsured patients, Amgen's free drug program can supply Repatha at no cost to qualifying patients with household income below 600% of the federal poverty level [12].

State Pharmaceutical Assistance Programs: West Virginia does not operate a standalone state pharmaceutical assistance program for lipid-lowering drugs as of this writing. Patients should inquire about the WVPATH program for broader medication assistance eligibility [13].

503A Compounding Pharmacies and Evolocumab in West Virginia

503A pharmacies in West Virginia are licensed to compound patient-specific preparations under physician supervision, but evolocumab itself is a biologic monoclonal antibody manufactured by Amgen under FDA-approved conditions [2]. 503A pharmacies cannot legally compound a biologic equivalent of evolocumab; the molecule requires recombinant cell-line manufacturing that is outside the scope of 503A compounding. West Virginia Board of Pharmacy regulations align with federal law on this point [14].

What 503A pharmacies in WV can do is prepare ancillary supplies (injection site care kits, diluents for other injectables) and serve as the dispensing pharmacy for commercially manufactured Repatha once a prescription is received. If a telehealth provider directs your Repatha prescription to a WV-licensed 503A pharmacy with specialty capabilities, the pharmacy fills it using the commercially manufactured Amgen product, not a compounded version.

Transferring an Existing Repatha Prescription to West Virginia

Patients relocating to West Virginia with an active Repatha prescription from another state can transfer that prescription to a WV-licensed pharmacy under standard prescription transfer rules. Specialty medications on prior authorization present one complication: the original insurer's PA approval does not automatically transfer. A new PA under the WV plan must be submitted.

The key steps are:

1. Ask your current specialty pharmacy to transfer the prescription to a WV pharmacy.
2. Provide your new WV prescriber (or telehealth provider) with your current PA approval letter and most recent lipid panel.
3. The new WV prescriber submits a fresh PA to your new insurer, citing the existing approval as supporting documentation.
4. Processing typically takes 5 to 14 business days for new PA [11].

If you are changing insurance plans at the time of relocation, expect to restart the PA process from scratch. Gather your statin trial documentation before you move to avoid delays.

Monitoring After Starting Repatha

Evolocumab does not require routine laboratory monitoring in the same way that statins require periodic liver function checks. The ACC/AHA recommends a fasting lipid panel at 4 to 12 weeks after initiating or adjusting lipid-lowering therapy and every 3 to 12 months thereafter to confirm adherence and treatment response [3].

In FOURIER, the median achieved LDL-C on evolocumab was 30 mg/dL, and no statistically significant safety signal emerged for neurocognitive effects, new-onset diabetes, or cataracts at that level [1]. A separate dedicated neurocognitive safety trial, EBBINGHAUS (N=1,974), found no difference in cognitive function between evolocumab and placebo groups over a median 19 months of follow-up [15]. West Virginia prescribers sometimes ask about this given older patients with dementia concerns; the trial data are reassuring.

Injection site reactions occur in approximately 2.1% of patients on evolocumab versus 1.6% on placebo in clinical trials [2]. Rotate injection sites between the abdomen, upper arm, and thigh. Rotating sites with each injection reduces local skin reaction risk.

Dosing Summary for West Virginia Patients

Two dosing options are FDA-approved [2]:

• 140 mg subcutaneous injection every 2 weeks (single-use prefilled autoinjector or prefilled syringe)
• 420 mg subcutaneous injection once monthly (three consecutive 140 mg injections within 30 minutes, or a single-use prefilled cartridge with the Pushtronex on-body infusor)

Both regimens produce equivalent LDL-C reductions of approximately 60% from baseline in clinical trials [1]. Patient preference and adherence pattern should guide the choice. Patients who travel frequently often prefer the monthly 420 mg dose for scheduling flexibility.

Store Repatha between 36°F and 77°F (2°C to 25°C). The autoinjector may be kept at room temperature (below 77°F) for up to 30 days. Do not freeze [2].